Technology
Health
Pharmaceutical

ContraVir

$0.2352
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0213 (-8.30%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ContraVir and other stocks, options, ETFs, and crypto commission-free!

About

ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for treatment of chronic liver disease. Its product candidates are CRV431, a novel drug candidate designed to target a class of proteins called cyclophilins; and TXL, a novel lipid acyclic nucleoside phosphonate that is designed to deliver high intracellular concentrations of the active antiviral agent tenofovir diphosphate. Read More The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Employees
14
Headquarters
Edison, New Jersey
Founded
2013
Market Cap
4.26M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
261.48K
High Today
$0.26
Low Today
$0.22
Open Price
$0.2555
Volume
126.82K
52 Week High
$2.60
52 Week Low
$0.2128

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2014 IPO
US
North America

Earnings

-$0.63
-$0.41
-$0.20
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.37 per share
Actual
Expected Mar 26, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.